Increasing the participation of African American men in prostate cancer clinical trials through education, awareness, support and collaborations. This portal provides clinical trials background information, details for specific trials, personal stories and other resources to support the Rally.

This information is not intended as medical advice for patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

"We must not be left behind with new prostate cancer treatments." PHEN president and founder Thomas A. Farrington talks about his prostate cancer journey and the importance of African American men participating in clinical trials. Information	Understanding the possible benefits for patients when participating in a clinical trial. Clinical trials offer important and unique benefits to patients. Information
Dr. J. Carter Presents Clinical Trials 101 Dr. Carter's brief video presentations provide basic information for patients to better understand clinical trials. Information	What Are Clinical Trials? Information that all patients need to know when considering enrolling into a clinical trial. Information
A Clinical Trials Guide for Patients Patient information on why clinical trials matter, how clinical trials work, what to expect, myths and facts. Information provided by Sanofi. Information	Quest The QUEST study is for men with metastatic prostate cancer (which means that cancer has spread to other parts of the body such as bones, liver or lung), who have already received androgen receptor (AR)-targeted therapy, but the cancer has still progressed. Information
KEYLYNK 010 This clinical trial is for men who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond abiraterone acetate or enzalutamide (but not both) and to chemotherapy. Information	KEYNOTE 921 This clinical trial is for men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy, and failed prior treatment with enzalutamide, abiraterone, and apalutamide. Information
KEYNOTE 641 This clinical trial is for men with men with metastatic castration-resistant prostate cancer (mCRPC) and is trying to find out if combining pembrolizumab and enzalutamide can slow down prostate cancer. Information	AMG 160 This clinical trial is to determine the safety, tolerability, pharmacokinetics, and efficacy of AMG 160 in men with metastatic castration-resistant prostate cancer (mCRPC). Information
PROTEUS Patient Summary The PROTEUS study is a randomized, double-blind, placebo-controlled, phase 3 study of an investigational drug in subjects with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy. Information	MAGNITUDE Patient Summary The MAGNITUDE Study is a Phase 3 randomized, placebo-controlled, double-blind study comparing a combination of an investigational medicine and standard treatment , to a combination of a placebo and standard treatment for men with metastatic prostate cancer. Information
ProVent Patient Summary This trial is for patients diagnosed with localized prostate cancer who have not yet received any active treatment and are planning on pursuing active surveillance. Information	TALAPRO-1 This trial is for patients with metastatic Castration-Resistant Prostate Cancer with certain mutations in DNA-damage-repair genes and who previously received taxane-based chemotherapy and progressed on enzalutamide or abiraterone. Information
TALAPRO-2 This trial is for patients with metastatic Castration-Resistant Prostate Cancer who have not received prior treatment for Castrate-Resistant disease. Information	Galahad Clinical Trial This trial is looking for men in the US with metastatic prostate cancer and certain genetic alterations within their tumors. Patients who progress on prior chemotherapy (taxane) and androgen receptor targeted therapy are eligible for this study. Information
CA209-9KD This is a clinical research study for men with metastatic prostate cancer (cancer that has spread) that no longer responds to androgen deprivation therapy treatments that lower testosterone. Information	Triton 2 Clinical Trial For patients with metastatic castration resistant prostate cancer that is progressing following treatment with Zytiga, Xtandi, and taxane based chemotherapy Information
Triton 3 Clinical Trial For patients where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of BRCA1, BRCA2, or ATM genetic mutations or alterations Information	Patients with Low and Intermediate Risk Prostate Cancer Clinical trials for patients who are diagnosed with low and intermediate risk prostate cancer (Gleason 6 or 7). Patients may be interested in active surveillance or making a decision to begin active treatment Information
High Risk Prostate Cancer Patients Clinical trials for patients diagnosed with high risk prostate cancer (Gleason 8 - 10). Patients may be deciding on an active treatment protocol. Information	Patients Treated with Prostatectomy or Radiation Clinical trials for patients who have been treated with surgery or radiation. Patients may be seeking to reduce the risk of recurrence following primary treatment or interested in quality of life studies. Information
Patients with Recurrent Prostate Cancer Clinical trials for patients who have a recurrence of prostate cancer following primary treatment with surgery or radiation.These patients have not yet begun treatment with androgen deprivation therapy. Information	Patients with Castration Resistant Prostate Cancer (CRPC) Clinical trials for patients whose PSA rises while they are on androgen deprivation therapy but prostate cancer has not metastasized. Patients who are seeking treatment options following this diagnosis of CRPC. Information
Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Clinical trials for patients diagnosed with metastatic prostate cancer that no longer responds to androgen deprivation treatment. Patients who are seeking treatment options following a diagnosis of mCRPC. Information